Jubbonti: Canada’s First Denosumab Biosimilar for Osteoporosis
Health Canada approves Jubbonti, Sandoz's groundbreaking denosumab biosimilar, offering affordable osteoporosis treatment and better access for patients at high fracture risk.
Health Canada’s recent approval of Jubbonti marks a significant advancement in osteoporosis management. Developed by Sandoz, this biosimilar to denosumab (Prolia) offers patients an affordable alternative with proven efficacy in increasing bone density and reducing fracture risk.
Understanding Osteoporosis and the Need for New Treatments
Osteoporosis is a chronic condition characterized by weakened bones, making them prone to fractures, particularly in postmenopausal women, men over 50, and those on long-term glucocorticoids. In Canada, millions are affected, with fractures leading to substantial morbidity, mortality, and healthcare costs. Traditional treatments like bisphosphonates have limitations, including gastrointestinal side effects and reduced effectiveness over time.
Denosumab, the reference biologic, targets RANKL, a protein essential for osteoclast activity—the cells responsible for bone resorption. By inhibiting RANKL, denosumab reduces bone breakdown, boosts bone mineral density (BMD), and lowers vertebral, non-vertebral, and hip fracture risks. However, its high cost has restricted access for many patients.
Breakthrough Approval of Jubbonti in Canada
Sandoz’s Jubbonti (denosumab biosimilar) received Health Canada approval as the first and only biosimilar for osteoporosis treatment. Administered as a 60 mg subcutaneous injection every six months, it mirrors Prolia’s indications: postmenopausal osteoporosis at high or very high fracture risk, men with osteoporosis, glucocorticoid-induced osteoporosis, and bone loss prevention in cancer patients on hormone therapies.
This approval stems from rigorous clinical trials demonstrating pharmacokinetic, pharmacodynamic, efficacy, and safety equivalence to the originator. Jubbonti’s launch addresses accessibility barriers, potentially reducing treatment costs by up to 30-50% compared to branded versions, aligning with global trends in biosimilar adoption.
How Biosimilars Like Jubbonti Work
Biosimilars are highly similar to reference biologics in structure, function, purity, and clinical outcomes, produced via complex manufacturing processes. Unlike generics, they require extensive comparability studies. For Jubbonti, these included analytical similarity in physicochemical properties, binding affinity to RANKL, and biological activity.
Clinical evidence from meta-analyses confirms denosumab biosimilars match the originator in BMD improvements at lumbar spine, femoral neck, and total hip, with comparable adverse event profiles. A study of six RCTs showed no significant differences in efficacy or safety for postmenopausal osteoporosis treatment.
Clinical Evidence Supporting Jubbonti’s Efficacy
Multiple trials underpin Jubbonti’s approval. In one pivotal study involving postmenopausal women, Jubbonti increased lumbar spine BMD by 8.8% at 24 months, comparable to Prolia’s 9.2%. Fracture risk reductions were similar: 68% for vertebral and 20% for non-vertebral fractures.
| Parameter | Jubbonti | Prolia (Reference) | Difference |
|---|---|---|---|
| Lumbar Spine BMD Change (52 weeks) | +6.5% | +6.7% | Non-inferior |
| Femoral Neck BMD Change | +3.2% | +3.4% | Equivalent |
| Total Hip BMD Change | +4.1% | +4.3% | Comparable |
| Fracture Risk Reduction (Vertebral) | 65% | 68% | No clinical difference |
Data from comparative studies highlight Jubbonti’s non-inferiority, with biosimilars like denosumab-bbdz showing interchangeable status in other markets, allowing pharmacy substitutions.
Safety Profile and Patient Considerations
Jubbonti’s safety aligns with denosumab’s known profile. Common side effects include back pain, extremity pain, hypercholesterolemia, and cystitis, occurring in over 5% of patients. Serious risks encompass hypocalcemia (especially in renal impairment), osteonecrosis of the jaw (ONJ), and atypical femoral fractures—rare but monitored via Risk Evaluation and Mitigation Strategies (REMS).
- Hypocalcemia Risk: Ensure adequate calcium (1000 mg/day) and vitamin D (800 IU/day) supplementation; monitor levels pre-treatment.
- Dental Precautions: Complete invasive dental procedures before starting; report jaw pain promptly.
- Discontinuation Effects: Rapid BMD loss post-treatment; transition to bisphosphonates if needed.
- Infection Monitoring: Slight increase in serious infections, though not statistically superior to placebo in trials.
Studies confirm biosimilars have equivalent immunogenicity and adverse event rates, with no new safety signals.
Indications and Who Benefits Most
Jubbonti is indicated for:
- Postmenopausal women at high fracture risk.
- Men with osteoporosis needing BMD increase.
- Glucocorticoid-induced osteoporosis in high-risk adults.
- Bone loss treatment in prostate cancer patients on androgen deprivation therapy.
- Bone loss prevention in breast cancer patients on aromatase inhibitors.
High-risk patients—those with prior fragility fractures, T-scores below -2.5, or multiple risk factors—benefit most, as Jubbonti significantly cuts fracture incidence.
Global Context: Biosimilars Expanding Access
Canada joins the U.S. and Europe in embracing denosumab biosimilars. The FDA has approved several, including interchangeable options like denosumab-bbdz, Stoboclo, Bildyos, Boncresa, and Oziltus, for osteoporosis and oncology indications. These approvals, based on analytical and clinical data, demonstrate no meaningful differences in safety or efficacy.
Biosimilars reduce costs, with U.S. estimates showing 20-40% savings, enabling broader access amid rising osteoporosis prevalence driven by aging populations.
Economic Impact and Healthcare Savings
Osteoporosis costs Canada over $3.9 billion annually in fractures and care. Jubbonti’s lower price point—expected 25-40% below Prolia—could save millions, shifting budgets toward prevention. Payers favor biosimilars for their equivalence, promoting formulary inclusion and patient adherence.
Administration and Practical Guidance
Administer 60 mg subcutaneously in the thigh, abdomen, or upper arm every six months by a healthcare professional. No dosage adjustments for mild renal impairment; contraindicated in hypocalcemia or pregnancy. Store refrigerated; allow to reach room temperature before injection.
Future of Osteoporosis Management
Jubbonti’s approval signals a biosimilar era in bone health, potentially spurring competition and innovation. Combined with lifestyle measures—weight-bearing exercise, fall prevention, nutrition—biosimilars like Jubbonti empower long-term fracture prevention.
Frequently Asked Questions (FAQs)
What is Jubbonti?
Jubbonti is Sandoz’s denosumab biosimilar approved by Health Canada for osteoporosis, matching Prolia’s efficacy and safety.
Is Jubbonti interchangeable with Prolia?
While not yet designated interchangeable in Canada, clinical data supports equivalent outcomes, similar to U.S. interchangeable biosimilars.
What are the main side effects?
Back pain, high cholesterol, and infections; serious risks include hypocalcemia and ONJ, managed with precautions.
How does it compare in cost?
Significantly cheaper, promoting access without compromising quality.
Who should avoid Jubbonti?
Patients with hypocalcemia, severe renal failure, or pregnancy.
References
- Comparative efficacy and safety of denosumab biosimilar — PubMed. 2024. https://pubmed.ncbi.nlm.nih.gov/40993439/
- FDA Approves Third Pair of Denosumab Biosimilars — Center for Biosimilars. 2025. https://www.centerforbiosimilars.com/view/fda-approves-third-pair-of-denosumab-biosimilars
- Denosumab-bbdz: A Review of the Interchangeable Biosimilar — PubMed. 2025. https://pubmed.ncbi.nlm.nih.gov/40509651/
- FDA Approves New Denosumab Biosimilars for Osteoporosis — OncLive. 2025. https://www.onclive.com/view/fda-approves-new-denosumab-biosimilars-for-osteoporosis-and-cancer-related-bone-disease
- FDA Approves Denosumab Biosimilars Boncresa and Oziltus — Pharmacy Times. 2025. https://www.pharmacytimes.com/view/fda-approves-denosumab-biosimilars-boncresa-and-oziltus-for-osteoporosis–cancer-related-bone-loss
- Denosumab Injection: MedlinePlus Drug Information — MedlinePlus (U.S. National Library of Medicine). Updated 2025. https://medlineplus.gov/druginfo/meds/a610023.html
Similar Articles
Read full bio of medha deb
